Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; the anti-cancer AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma; Radiopharmaceuticals program; the ARM-X vaccine program, a mesenchymal stem cell-based vaccine targeting cancer; and mRNA vaccination program. The company also offers Dendritic Cell (DC) cancer vaccines using Accum; a protein-based vaccine formulation against COVID and infectious diseases; and a cervical cancer vaccine. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. The company was incorporated in 2017 and is headquartered in Montreal, Canada.…
Defence Therapeutics Invites Shareholders to Its December 10, 2026, Annual General Meeting and 2027 Strategic Update
Defence Therapeutics (CNSX: DTC) is listed on the Canadian Securities Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 0.2500 CAD on 20 November 2026, down 69.1% over 52 weeks. Its 52-week range is 0.2200 CAD to 0.9300 CAD: the price is 73.1% below the high and 13.6% above the low.
Its market capitalisation is 19.03M CAD.
Defence Therapeutics reports return on equity of -154.8% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 161.32K CAD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.
No upcoming events tracked.